HomeORGANIZATION
ORGANIZATION

Reflecting Results of CEA in NHI Prices at Time of Listing Will Be Difficult: FPMAJ Report
(Jun.20.2017)

The Federation of Pharmaceutical Manufacturers’ Associations of Japan’s (FPMAJ) committee on drug pricing affairs presented its views on cost-effective assessments (CEAs) in a report announced on June 16. The report points out that it is not recommendable to reflect the results of CEAs in the NHI prices of new drugs at the time of their listing because it is time-consuming ...
(LOG IN FOR FULL STORY)

News Calendar